Literature DB >> 6359845

Clinical outcome after treatment of rest angina with calcium blockers: comparative experience during the initial year of therapy with diltiazem, nifedipine, and verapamil.

C J Pepine, R L Feldman, J A Hill, C R Conti, J Mehta, C Hill, E Scott.   

Abstract

The clinical outcome after the initial year of therapy with either diltiazem (D), nifedipine (N), or verapamil (V) was examined in 45 patients with rest angina. Age, frequency of angina, duration of symptoms, and ejection fraction were similar in all three treatment groups. Coronary artery disease was present in 60% of patients (5 of 13 given D, 8 of 16 given N, and 14 of 16 given V). Coronary spasm was suspected (ST elevation with angina) or documented (angiographically) in 35 (78%) patients. Twenty-nine (64%) patients had greater than 50% decrease in angina without a coronary event (9 taking D, 11 taking N, and 9 taking V). Coronary events (sudden death, infarction, and hospitalization for unacceptable angina control or bypass surgery) occurred in 13 (29%) patients (two taking D, four taking N, and seven taking V). To achieve these responses, 20 (44%) patients required additional antianginal drugs (long-acting nitrates, beta blockers, or other calcium blockers). Four of these 20 patients were taking D, nine were taking N, and seven were taking V. Seventeen (38%) patients experienced a side effect (none taking D, 6 taking N, and 11 taking V). Although rest angina can be controlled in the majority of patients during the initial year of treatment with calcium blockers, additional therapy is often required. Furthermore, the clinical course of patients presenting with rest angina remains unpredictable, even during calcium blocker treatment. Morbid events continue to occur, related in part to the extent of coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6359845     DOI: 10.1016/0002-8703(83)90043-1

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  11 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

2.  Calcium channel blockers and the emergency care kit in the dental office.

Authors:  T Kosmac
Journal:  Anesth Prog       Date:  1985 Sep-Oct

3.  Effect of nifedipine and propranolol on blood flow, venous compliance and blood pressure in essential hypertension.

Authors:  R I Ogilvie
Journal:  Can Med Assoc J       Date:  1985-05-15       Impact factor: 8.262

Review 4.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

5.  Prevention of vasospastic angina with nicardipine.

Authors:  C J Pepine; J S Gelman
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

6.  Tiapamil, a new calcium channel blocking agent for the treatment of effort induced chronic stable angina pectoris.

Authors:  N S Khurmi; C W Robinson; M J O'Hara; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  A comparison of nine calcium ion antagonists and propranolol: exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris.

Authors:  N S Khurmi; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 8.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

9.  Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine, tiapamil and verapamil) in patients with chronic stable angina pectoris.

Authors:  N S Khurmi; E B Raftery
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

Review 10.  Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.